dr. west on emerging changes in the field of egfr-mutant nsclc
Published 7 years ago • 212 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
1:01
dr. shum on emerging targeted therapies in egfr-mutant nsclc
-
2:03
dr. west on considering factors for egfr tkis in nsclc
-
3:14
dr. west on fda approval of frontline osimertinib in egfr nsclc
-
20:34
2021 west oncology | lung cancer | egfr mutation therapy resistance and adcs and trop2
-
0:40
copy of dr. west on fda approval of frontline osimertinib in egfr nsclc
-
7:08
emerging data in egfr-mutant lung cancer
-
37:44
deciphering the data in egfr - mutant nsclc
-
6:02
egfr mutation and cancer
-
5:07
christie’s story: metastatic lung cancer survivor
-
21:07
lung cancer stage 4 :tagrisso (tumor pill) side effects - visible after 9days
-
0:48
dr. govindan on the future of egfr-mutant nsclc
-
2:02
evolutions in the treatment of egfr-mutated nsclc
-
1:57
dr. piotrowska on treatment for egfr-mutant nsclc
-
1:29
dr. bertino on the impact of the egfr-mutated subset analysis of impower150 in nsclc
-
2:11
dr. low on osimertinib versus dacomitinib in egfr-mutant nsclc
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
2:23
dr. zhu on primary resistance to osimertinib in egfr-mutant nsclc
-
1:15
dr. aggarwal on triplet therapy in egfr-mutant lung cancer
-
1:58
dr. bazhenova on sequencing beyond progression in egfr-mutant nsclc
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc
-
1:34
dr. fidler on the utility of dacomitinib in egfr-mutant nsclc